In the latest session, MoonLake Immunotherapeutics (NASDAQ: MLTX) closed at $50.59 up 4.18% from its previous closing price of $48.56. In other words, the price has increased by $+2.03 from its previous closing price. On the day, 600772 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a deeper understanding of MoonLake Immunotherapeutics’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 51.59 and its Current Ratio is at 51.59. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wolfe Research on February 15, 2024, initiated with a Outperform rating and assigned the stock a target price of $77.
On December 08, 2023, Citigroup started tracking the stock assigning a Buy rating and target price of $72.
On November 02, 2023, Stifel started tracking the stock assigning a Buy rating and target price of $74.Stifel initiated its Buy rating on November 02, 2023, with a $74 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 29 ’24 when Santos da Silva Jorge sold 4,740 shares for $55.89 per share. The transaction valued at 264,919 led to the insider holds 2,982,814 shares of the business.
Santos da Silva Jorge sold 56,065 shares of MLTX for $3,083,575 on Feb 28 ’24. The Chief Executive Officer now owns 2,987,554 shares after completing the transaction at $55.00 per share. On Feb 28 ’24, another insider, Reich Kristian, who serves as the Chief Scientific Officer of the company, sold 31,910 shares for $55.00 each. As a result, the insider received 1,755,050 and left with 2,925,573 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLTX now has a Market Capitalization of 3.06B and an Enterprise Value of 2.55B.
Stock Price History:
Over the past 52 weeks, MLTX has reached a high of $64.98, while it has fallen to a 52-week low of $17.82. The 50-Day Moving Average of the stock is 54.52, while the 200-Day Moving Average is calculated to be 51.69.
Shares Statistics:
For the past three months, MLTX has traded an average of 478.66K shares per day and 606.28k over the past ten days. A total of 60.47M shares are outstanding, with a floating share count of 47.19M. Insiders hold about 21.27% of the company’s shares, while institutions hold 98.47% stake in the company. Shares short for MLTX as of Feb 29, 2024 were 6.94M with a Short Ratio of 14.50, compared to 6.67M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 11.04% and a Short% of Float of 20.28%.
Earnings Estimates
There are 10 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.2 for the current quarter, with a high estimate of -$0.13 and a low estimate of -$0.3, while EPS last year was -$0.23. The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.13 and low estimates of -$0.47.
Analysts are recommending an EPS of between -$0.52 and -$1.93 for the fiscal current year, implying an average EPS of -$1.19. EPS for the following year is -$1.8, with 10 analysts recommending between -$0.7 and -$2.87.
